Alain Luxembourg
Overview
Explore the profile of Alain Luxembourg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1726
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carter J, Smith R, Scherer E, Skibinski D, Sankaranarayanan S, Luxembourg A, et al.
Vaccine
. 2025 Mar;
54:126974.
PMID: 40054143
No abstract available.
2.
Carter J, Smith R, Scherer E, Skibinski D, Sankaranarayanan S, Luxembourg A, et al.
Vaccine
. 2025 Feb;
50:126817.
PMID: 39914257
Human papillomavirus (HPV) vaccines provide excellent protection from infection and disease. The minimum number of doses needed for long-term protection and the potential need for boosters are areas of continuing...
3.
Giuliano A, Palefsky J, Goldstone S, Bornstein J, De Coster I, Guevara A, et al.
Hum Vaccin Immunother
. 2025 Jan;
21(1):2425146.
PMID: 39840832
Post hoc analyses of 9-valent human papillomavirus (9vHPV) vaccine immunogenicity were conducted in five Phase 3 studies that enrolled males. Month 7 antibody geometric mean titers (GMTs) after three 9vHPV...
4.
Kjaer S, Falkenthal T, Sundstrom K, Munk C, Sture T, Bautista O, et al.
Hum Vaccin Immunother
. 2024 Oct;
20(1):2377903.
PMID: 39373579
A pivotal study in women aged 16-26 years demonstrated that the nine-valent human papillomavirus (9vHPV) vaccine was efficacious against high-grade cervical dysplasia related to the HPV types covered by the...
5.
Klein N, Wiesner A, Bautista O, Group T, Kanu K, Li Z, et al.
Pediatrics
. 2024 Jul;
154(2).
PMID: 38978512
Background: Nine-valent human papillomavirus (9vHPV) vaccines can be administered in 2 doses 6 to 12 months apart in adolescents. The impact of extended dose intervals is unknown. We report immunogenicity...
6.
Giuliano A, Palefsky J, Goldstone S, Dubin B, Saah A, Luxembourg A, et al.
J Infect Dis
. 2023 Nov;
229(3):707-718.
PMID: 38012959
Background: International data on anogenital HPV infection incidence among men are limited. Methods: Incidence of incident-persistent (IP) anogenital HPV infections was evaluated among 295 men who have sex with men...
7.
Restrepo J, Herrera T, Samakoses R, Reina J, Pitisuttithum P, Ulied A, et al.
Pediatrics
. 2023 Sep;
152(4).
PMID: 37667847
Background And Objectives: The 9-valent human papillomavirus (9vHPV) vaccine Phase III immunogenicity study in 9- to 15-year-old boys and girls was extended to assess immunogenicity and effectiveness through 10 years...
8.
Nolan K, Seaton B, Antonello J, Zhang Y, Cook L, Delfino K, et al.
mSphere
. 2023 Mar;
8(2):e0096221.
PMID: 36926984
Two multiplex immunoassays are routinely used to assess antibody responses in clinical trials of the 9-valent human papillomavirus (9vHPV) vaccine. The HPV6/11/16/18/31/33/45/52/58 competitive Luminex immunoassay (HPV-9 cLIA) and HPV6/11/16/18/31/33/45/52/58 total...
9.
Wang W, Kothari S, Skufca J, Giuliano A, Sundstrom K, Nygard M, et al.
Expert Rev Vaccines
. 2022 Sep;
21(12):1799-1817.
PMID: 36178094
Introduction: Human papillomavirus (HPV) infection, which poses significant disease burden, is decreasing following implementation of vaccination programs. Synthesized evidence on HPV vaccine real-world benefit was published in 2016. However, long-term...
10.
Garland S, Anagani M, Bhatla N, Chatterjee S, Lalwani S, Ross C, et al.
Hum Vaccin Immunother
. 2022 Aug;
18(6):2105067.
PMID: 35997582
The quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) and 9-valent HPV (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccines have demonstrated efficacy, immunogenicity, and safety in international clinical trials. We report outcomes from three completed clinical trials...